Replies to post #208855 on Biotech Values

[DewDiligence]

Corrected—4Q16 HCV/ GT1: Harvoni vs Viekira* vs Zepatier ($ M)

[Replaced Zepatier estimates by actual figs (h/t ‘Rocky3’);
table excludes GILD’s Epclusa and standalone Sovaldi,
which are almost exclusively used for GT2/GT3 patients.]

 
 Worldwide  
 Harvoni         1640  75.2% 
 Viekira          311  14.2% 
 Zepatier         229  10.5% 
 ========        ==== ====== 
 Total           2180 100.0% 
  
 US  
 Harvoni          976  80.7% 
 Viekira           54   4.5% 
 Zepatier         180  14.9% 
 ========        ==== ====== 
 Total           1210 100.0% 
  
 Ex-US  
 Harvoni          664  68.5% 
 Viekira          257  26.5% 
 Zepatier          49   5.1% 
 ========        ==== ====== 
                  970 100.0%

*Includes Viekirax/Technivie (2-DAA) brands.